Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Capital Expenditures: 2010-2024

Historic Capital Expenditures for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $38,411.

  • China Pharma Holdings' Capital Expenditures rose 106.63% to $611 in Q3 2025 from the same period last year, while for Sep 2025 it was $78,415, marking a year-over-year increase of 34.59%. This contributed to the annual value of $38,411 for FY2024, which is 233.52% up from last year.
  • Per China Pharma Holdings' latest filing, its Capital Expenditures stood at $38,411 for FY2024, which was up 233.52% from $11,517 recorded in FY2023.
  • Over the past 5 years, China Pharma Holdings' Capital Expenditures peaked at $867,307 during FY2020, and registered a low of $11,517 during FY2023.
  • Over the past 3 years, China Pharma Holdings' median Capital Expenditures value was $38,411 (recorded in 2024), while the average stood at $150,631.
  • In the last 5 years, China Pharma Holdings' Capital Expenditures skyrocketed by 537.71% in 2020 and then tumbled by 97.13% in 2023.
  • Yearly analysis of 5 years shows China Pharma Holdings' Capital Expenditures stood at $867,307 in 2020, then plummeted by 49.49% to $438,055 in 2021, then dropped by 8.24% to $401,964 in 2022, then tumbled by 97.13% to $11,517 in 2023, then soared by 233.52% to $38,411 in 2024.